RENO, Nev. (August 13th, 2019)The Orthopaedic Implant Company (“OIC”) today announced the release of its Trochanteric Antegrade Femur Intramedullary Nail (“TAFN”). The TAFN is part of the OIC Intramedullary Nail System, designed to support surgeons and facilities in successfully moving from fee-for-service to value-based care.
The TAFN is indicated for simple and comminuted fractures occurring in and between the proximal third and distal fourth of the femur. It is available in diameters ranging from ten to thirteen millimeters and 320 to 440 millimeters in length. “Our focus in design is simplicity and consistency. Because it utilizes instrumentation surgeons already use, it’s instantly familiar and an obvious device to select for the appropriate indications,” said Todd Martens, VP of Design and Customer Experience.
In addition to the TAFN, the OIC IM Nail System includes hip nails, a piriformis-entry antegrade and retrograde femur nail, as well as a tibial nail indicated for infra- and suprapatellar approaches.
About The Orthopaedic Implant Company:
Not just another vendor, The Orthopaedic Implant Company (OIC) is the leading high-value orthopaedic implant manufacturer whose mission is to offer the highest quality implants at the lowest possible prices. In doing so, OIC provides surgeons and facilities with the value they rely on to successfully meet the challenges of value-based care. OIC implants can be used for a variety of procedures, including treatment of orthopaedic trauma and sports injuries. All OIC products are FDA-approved and manufactured in FDA-approved facilities.